Antiepileptic drug treatment in patients with Parkinson's disease;Fármacos antiepilépticos en la enfermedad de Parkinson

Medicina Clinica

Volumn 131, Issue 12, 2008, Pages 466-470

  Emilio Bermejo, Pedro ^a   María Gómez Argüelles, José ^a   Manuel Sepúlveda, Juan ^a  

^a Unidad de Trastornos   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTICONVULSIVE AGENT; BENSERAZIDE; CARBIDOPA; ENTACAPONE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LEVODOPA; PLACEBO; PREGABALIN; RASAGILINE; SELEGILINE; TIAGABINE; TOLCAPONE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ARTICLE; BULIMIA; DEMENTIA; DEPRESSION; EPILEPSY; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; KLEPTOMANIA; LEWY BODY; MOTOR DYSFUNCTION; NEUROPROTECTION; PARKINSON DISEASE; PSYCHOSIS; TREMOR;

ANTICONVULSANTS; HUMANS; PARKINSON DISEASE;

EID: 63149153481     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13126957     Document Type: Article

References (78)

1. Buck M.L., Gurka M.J., and Goodkin H.P. Postmarketing modifications in the safety labeling of the new antiepileptics. Neurology 68 (2007) 1536-1537
2. Bermejo P.E., and Velasco R. Nuevos fármacos antiepilépticos en la prevención de la migraña. Med Clin (Barc) 128 (2007) 379-382
3. Bermejo P.E., and Velasco R. Nuevos fármacos antiepilépticos y dolor neuropático. De la medicina molecular a la clínica. Med Clin (Barc) 129 (2007) 542-550
4. Bermejo P.E. Tratamiento del temblor esencial. Med Clin (Barc) 129 (2007) 222-227
5. Bandelow B., Wedekind D., and Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 7 (2007) 769-781
6. Dannon P.N., Lowengrub K., Gonopolski Y., Musin E., and Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 28 (2005) 6-10
7. El Yaman S.H., Mroueh S.M., Sinno D.D., and Mikati M.A. Long-term patterns of weight changes during topiramate therapy: an observational study. Neurology 69 (2007) 310-311
8. Roy Chengappa K., Kupfer D.J., Parepally H., John V., Basu R., Buttenfield J., et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord 9 (2007) 609-617
9. Bazil C.W. Anticonvulsant drug or neuromodulator? The growing case for anticonvulsant uses beyond epilepsy. Curr Neurol Neurosci Rep 4 (2004) 305-307
10. Jankovic J. An update on the treatment of Parkinson's disease. Mt Sinai J Med 73 (2006) 682-689
11. Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des 10 (2004) 687-693
12. Kito M., Maehara M., and Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 5 (1996) 115-119
13. Gluck M.R., Santana L.A., Granson H., and Yahr M.D. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. J Neural Transm 111 (2004) 713-724
14. Chana P., De Marinis A., and Barrientos N. Gabapentin and motor fluctuations in Parkinson's disease. Mov Disord 12 (1997) 608
15. Van Blercom N., Lasa A., Verger K., Masramon X., Sastre V.M., and Linazasoro G. Effects of gabapentin on the motor response to levodopa: a doubleblind, placebo-controlled, crossover study in patients with complicated Parkinson disease. Clin Neuropharmacol 27 (2004) 124-128
16. Chen L., and Yung W.H. GABAergic neurotransmission in globus pallidus and its involvement in neurologic disorders. Sheng Li Xue Bao 56 (2004) 427-435
17. Nutt J., Williams A., Plotkin C., Eng N., Ziegler M., and Calne D.B. Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations. Can J Neurol Sci 6 (1979) 337-343
18. Zadikoff C., Munhoz R.P., Asante A.N., Politzer N., Wennberg R., Carlen P., et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 78 (2007) 147-151
19. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101 (2004) 9861-9866
20. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
21. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., and Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54 (2000) 1589-1595
22. Bermejo P.E., and Dorado R. Topiramato en el temblor esencial refractario. Rev Neurol 45 (2007) 188-189
23. Skradski S., and White H.S. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 41 (2000) 45-47
24. Silverdale M.A., Nicholson S.L., Crossman A.R., and Brotchie J.M. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord 20 (2005) 403-409
25. Huang C.W., Ueno S., Okada M., and Kaneko S. Zonisamide at clinically relevant concentrations inhibits field EPSP but not presynaptic fiber volley in rat frontal cortex. Epilepsy Res 67 (2005) 51-60
26. Hill M.P., Bezard E., McGuire S.G., Crossman A.R., Brotchie J.M., Michel A., et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by l-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 18 (2003) 1301-1315
27. Zesiewicz T., Sullivan K.L., Maldonado J.L., Tatum W.O., and Hauser R.A. Openlabel pilot study of levetiracetam (Keppra) for the treatment of levodopainduced dyskinesias in Parkinson's disease. Mov Disord 20 (2005) 1205-1219
28. Carunchio I., Pieri M., Ciotti M.T., Albo F., and Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia 48 (2007) 654-662
29. Chase T.N., and Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23 (2000) 86-91
30. Peixoto M.F., Abílio V.C., Silva R.H., and Frussa-Filho R. Effects of valproic acid on an animal model of tardive dyskinesia. Behav Brain Res 142 (2003) 229-233
31. Raju P.M., Walker R.W., and Lee M.A. Dyskinesia induced by gabapentin in idiopathic Parkinson's disease. Mov Disord 22 (2007) 288-289
32. Ziemssen T., and Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 13 (2007) 323-332
33. Carod-Artal F.J., Ziomkowski S., Mourao Mesquita H., and Martínez-Martín P. Anxiety and depression: main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. Parkinsonism Relat Disord 14 (2008) 102-108
34. Bandelow B., Wedekind D., and Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 7 (2007) 769-781
35. Verduin M.L., McKay S., and Brady K.T. Gabapentin in comorbid anxiety and substance use. Am J Addict 16 (2007) 142-143
36. Kinrys G., Worthington J.J., Wygant L., Nery F., Reese H., and Pollack M.H. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry 68 (2007) 1010-1013
37. Mirza N.R., Bright J.L., Stanhope K.J., Wyatt A., and Harrington N.R. Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels?. Psychopharmacology (Berl) 180 (2005) 159-168
38. Kinrys G., Vasconcelos e Sa D., and Nery F. Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract 61 (2007) 1050-1053
39. Klufas A., and Thompson D. Topiramate-induced depression. Am J Psychiatry 158 (2001) 1736
40. Wilson M.S., and Findling R.L. Zonisamide for bipolar depression. Expert Opin Pharmacother 8 (2007) 111-113
41. Ravindran L.N., and Ravindran A.V. Lamotrigine in the treatment of recurrent brief depression. Int Clin Psychopharmacol 22 (2007) 121-123
42. Yasmin S., Carpenter L.L., Leon Z., Siniscalchi J.M., and Price L.H. Adjunctive gabapentin in treatment-resistant depression: a retrospective chart review. J Affect Disord 63 (2001) 243-247
43. Galpern W.R., and Stacy M. Management of impulse control disorders in Parkinson's disease. Curr Treat Options Neurol 9 (2007) 189-197
44. McElroy S.L., Hudson J.I., Capece J.A., Beyers K., Fisher A.C., and Rosenthal N.R. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 61 (2007) 1039-1048
45. Dannon P.N., Lowengrub K., Gonopolski Y., Musin E., and Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 28 (2005) 6-10
46. Roig J., Carreño M.M., and Parellada E. Probable psicosis inducida por levetiracetam. Med Clin (Barc) 129 (2007) 278
47. Teive H.A., Arruda W.O., Munhoz R.P., and Werneck L.C. Topiramate-induced psychosis: report of two cases. Expert Opin Drug Saf 5 (2006) 741-742
48. Michael C.T., and Starr J.L. Psychosis following initiation of zonisamide. Am J Psychiatry 164 (2007) 682
49. Kashihara K. Weight loss in Parkinson's disease. J Neurol 253 (2006) 38-41
50. Carnero Fernández M., Morales Gorria M.J., Corredera García E., and Del Campo Pérez V. Pérdida de peso asociada a topiramato en pacientes epilépticos. Med Clin (Barc) 124 (2005) 636-637
51. Gadde K.M., Franciscy D.M., Wagner II H.R., and Krishnan K.R. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289 (2003) 1820-1825
52. Gelisse P., Juntas-Morales R., Genton P., Hillaire-Buys D., Díaz O., Coubes P., et al. Dramatic weight loss with levetiracetam. Epilepsia 49 (2008) 308-315
53. Friedman J.H., Brown R.G., Comella C., Garber C.E., Krupp L.B., Lou J.S., et al. Fatigue in Parkinson's disease: a review. Mov Disord 22 (2007) 297-308
54. Tariot P.N., Erb R., Podgorski C.A., Cox C., Patel S., Jakimovich L., et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 155 (1998) 54-61
55. Fhager B., Meiri I.M., Sjögren M., and Edman A. Treatment of aggressive behavior in dementia with the anticonvulsant topiramate: a retrospective pilot study. Int Psychogeriatr 15 (2003) 307-309
56. Devarajan S., and Dursun S.M. Aggression in dementia with lamotrigine treatment. Am J Psychiatry 157 (2000) 1178
57. Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 43 (1998) 69-72
58. Moretti R., Torre P., Antonello R.M., Cazzato G., and Bava A. Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation. Drugs Aging 20 (2003) 1035-1040
59. Rossi P., Serrao M., and Pozzessere G. Gabapentin-induced worsening of neuropsychiatric symptoms in dementia with lewy bodies: case reports. Eur Neurol 47 (2002) 56-57
60. Kyomen H.H., Whitfield T.H., and Baldessarini R.J. Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer's type. J Clin Psychopharmacol 27 (2007) 408-410
61. Löschmann P.A., Eblen F., Wullner U., Wachtel H., and Kockgether T. Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. Eur J Pharmacol 284 (1995) 129-134
62. Lagrue E., Chalon S., Bodard S., Saliba E., Gressens P., and Castelnau P. Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice. Pediatr Res 62 (2007) 14-19
63. Shinotoh H., Vingerhoets F.J., Lee C.S., Uitti R.J., Schulzer M., Calne D.B., et al. Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebocontrolled, crossover study. Neurology 48 (1997) 1282-1285
64. Gómez-Esteban J.C., Zarranz J.J., Tijero B., Velasco F., Barcena J., Rouco I., et al. Restless legs syndrome in Parkinson's disease. Mov Disord 22 (2007) 1912-1916
65. Trenkwalder C., Paulus W., and Walters A.S. The restless legs syndrome. Lancet Neurol 4 (2005) 465-475
66. Drake M.E. Restless legs with antiepileptic drug therapy. Clin Neurol Neurosurg 90 (1988) 151-154
67. Bermejo P.E., Zabala J.A., and Sáez R. Restless legs syndrome induced by zonisamide. Mov Disord 22 (2007) 1517-1518
68. Della Marca G., Vollono C., Mariotti P., Mazza M., Mennuni G.F., and Tonali P. Levetiracetam can be effective in the treatment of restless legs syndrome with periodic limb movements in sleep: report of two cases. J Neurol Neurosurg Psychiatry 77 (2006) 566-567
69. Lundvall O., Abom P.E., and Holm R. Carbamazepine in restless legs. A controlled pilot study. Eur J Clin Pharmacol 25 (1983) 323-324
70. Youssef E.A., Wagner M.L., Martínez J.O., and Hening W. Pilot trial of lamotrigine in the restless legs syndrome. Sleep Med 6 (2005) 89
71. Tan J., Derwa A., Sanu V., Rahman N., and Woodrow G. Gabapentin in treatment of restless legs syndrome in peritoneal dialysis patients. Perit Dial Int 26 (2006) 276-278
72. Sommer M., Bachmann C.G., Liebetanz K.M., Schindehütte J., Tings T., and Paulus W. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 115 (2007) 347-350
73. Romigi A., Izzi F., Placidi F., Sperli F., Cervellino A., and Marciani M.G. Topiramate-induced restless legs syndrome: a report of two cases. J Neurol 254 (2007) 1120-1121
74. Pérez Bravo A. Utilidad del topiramato en el tratamiento del síndrome de piernas inquietas. Actas Esp Psiquiatr 32 (2004) 132-137
75. Stockner H., Sojer M., Seppi K., Mueller J., Wenning G.K., Schmidauer C., et al. Midbrain sonography in patients with essential tremor. Mov Disord 22 (2007) 414-417
76. Okawa M., Miwa H., Kajimoto Y., Hama K., Morita S., Nakanishi I., et al. Transcranial sonography of the substantia nigra in Japanese patients with Parkinson's disease or atypical parkinsonism: clinical potential and limitations. Intern Med 46 (2007) 1527-1531
77. Zesiewicz T.A., Ward C.L., Hauser R.A., Sánchez-Ramos J., Staffetti J.F., and Sullivan K.L. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord 22 (2007) 279-282
78. Bermejo P.E. Zonisamide in patients with essential tremor and Parkinson's disease. Mov Disord 22 (2007) 2137-2138